Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

1998, Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group, Lancet, 352, 930, 10.1016/S0140-6736(98)03301-7 Joensuu, 1998, Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial, J Clin Oncol, 16, 3720, 10.1200/JCO.1998.16.12.3720 Chlebowski, 1989, Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group, Br J Cancer, 59, 227, 10.1038/bjc.1989.46 Smith, 1996, New treatments for breast cancer, Semin Oncol, 23, 506 Symon, 1999, Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, 72, 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 Gordon, 2001, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J Clin Oncol, 19, 3312, 10.1200/JCO.2001.19.14.3312 Gabizon, 1997, Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours, Drugs, 54, 15, 10.2165/00003495-199700544-00005 Ranson, 1997, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial, J Clin Oncol, 15, 3185, 10.1200/JCO.1997.15.10.3185 Fleming, 1997 Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 1998, Common Toxicity Criteria, version 2.0 Singal, 1998, Doxorubicin-induced cardiomyopathy, N Engl J Med, 339, 900, 10.1056/NEJM199809243391307 Von Hoff, 1979, Risk factors for doxorubicin-induced congestive heart failure, Ann Intern Med, 91, 710, 10.7326/0003-4819-91-5-710 Titgan, 1997, Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone, Proc Am Soc Clin Oncol, 16, 288a Vail, 1998, Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model, Clin Cancer Res, 4, 1567 Honecker, 2002, Reduction of skin toxicity of pegylated lipsomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine (PYR) in patients (PTS) with anthracycline-sensitive malignancies: a phase I/II trial, J Cancer Res Clin Oncol, 128, 848 Baas, 2000, Caelyx in malignant mesothelioma: a phase II EORTC study, Ann Oncol, 11, 697, 10.1023/A:1008346925273 Israel, 2000, Phase II study of liposomal doxorubicin in advanced gynecologic cancers, Gynecol Oncol, 78, 143, 10.1006/gyno.2000.5819 Muggia, 2002, Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study, J Clin Oncol, 20, 2360, 10.1200/JCO.2002.08.171 Safra, 2000, Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2, Ann Oncol, 11, 1029, 10.1023/A:1008365716693 Torti, 1986, Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy, Cancer Res, 46, 3722 Jain, 1985, A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer, J Clin Oncol, 3, 818, 10.1200/JCO.1985.3.6.818 Clin Oncol, 2000, Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment, J Clin Oncol, 18, 3115, 10.1200/JCO.2000.18.17.3115 Harris, 2002, Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma, Cancer, 94, 25, 10.1002/cncr.10201 Batist, 2001, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J Clin Oncol, 19, 1444, 10.1200/JCO.2001.19.5.1444